FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979906121> ?p ?o ?g. }

• W2979906121 abstract "Abstract Abstract 1723 Poster Board I-749 Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients (1). Interleukin-1 (IL-1) is a cytokine involved in the maturation and proliferation of B cells and plays a significant role in the development of lytic bone lesions, a major clinical feature of MM patients (pts). Previous studies demonstrated that the polymorphism of IL1b-31 significantly influenced overall survival, as reported in patients undergoing high-dose melphalan treatment followed by autologous-stem cell transplant (2). TNF-a, a potent mediator of inflammation and bone resorption, seems to be involved in the malignant transformation of plasma cells, since mononuclear cells, obtained from MM patients and exposed in vitro to TNF-a and interleukin-4, produced monoclonal plasma cells. In addition, TNF-a can stimulate plasma cell proliferation, by triggering interleukin-6 secretion, and shows proangiogenic properties in vitro. In addition, TNF-a determination was reported to be a good parameter for estimating tumor mass and for monitoring therapy outcome during treatment with different protocols. TNF-a is also able to activate NF-kB, which is the main target of bortezomib. Variation in TNF-a levels can be related to gene expression, which is regulated at transcriptional level, as well as to genetic polymorphism (SNP). Single nucleotide SNPs have been identified at position -308 and -238 in the gene promoter. Specifically, a G to A substitution at position -308 is associated with higher levels of TNF-a (3). TNFRSF1B is a member of the TNF-receptor superfamily. This protein through the recruitment of two anti-apoptotic proteins upgrades TNF-induced apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2. Knockout studies in mice also suggest a role of this protein in protecting neurons from apoptosis by stimulating antioxidative pathways (4). In this study, we investigated the correlation between the SNPs of IL1A -889, IL1B -511, IL1B -31, IL1RN -371 (interleukin 1 receptor antagonist), TNF-a -308 and TNFRSF1B -587 on the outcome of refractory and relapsed MM pts, receiving bortezomib containing regimen as second line therapy. From September 2005 to April 2009 we selected 98 MM pts, who received at least one cycle of chemotherapy before treatment with bortezomib and at least one cycle of high dose chemotherapy with peripheral blood stem cell transplantation in 25 pts. No associations between the SNPs at the loci regarding IL-1A, IL-1B, IL-1RN and clinical factors such as age, sex, clinical stage at onset and M-protein type were observed. TNF-a SNP at position -308 and TNFRSF1B SNP at position -587 were determined on genomic DNA extracted from blood samples. These genotypes frequencies obtained were in agreement with Hardy–Weinberg equilibrium. Patients were categorized as responders (complete + partial response = R) or non responders (stable + progression disease = NR) to treatment. The overall response in our patients was about 74.5% (73/98). In MM pts carrying the rarest A allele of TNF-a the overall response was reduced to 61% (14/23 pts), whilst GG carriers showed a better response rate of 79% (59/75pts)(OR=0.42). We obtained similar results from the analysis of TNFRSF1B SNP. Pts carrying the rarest G allele the overall response was reduced to 69% (27/39 pts), whilst TT carriers showed a better response rate of 79% (46/59pts). Our results indicate that the cytokines (IL-1A, IL-1B, IL-1RN) gene SNPs do not confer differences in the outcome of advanced MM. On the contrary TNF-a and TNFRSF1B SNPs seems to be independent factors to predict the response and the outcome in patients affected by MM and treated with bortezomib containing regimen. If these preliminary results will be confirmed, they may represent a rationale for targeting TNF-a in novel therapeutic approaches to MM. Disclosures No relevant conflicts of interest to declare." @default.
• W2979906121 created "2019-10-18" @default.
• W2979906121 creator A5007152738 @default.
• W2979906121 creator A5011287280 @default.
• W2979906121 creator A5016021915 @default.
• W2979906121 creator A5022153283 @default.
• W2979906121 creator A5044244099 @default.
• W2979906121 creator A5053624043 @default.
• W2979906121 creator A5068166657 @default.
• W2979906121 creator A5069161646 @default.
• W2979906121 creator A5072006834 @default.
• W2979906121 creator A5083084021 @default.
• W2979906121 date "2009-11-20" @default.
• W2979906121 modified "2023-09-28" @default.
• W2979906121 title "Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B." @default.
• W2979906121 doi "https://doi.org/10.1182/blood.v114.22.1723.1723" @default.
• W2979906121 hasPublicationYear "2009" @default.
• W2979906121 type Work @default.
• W2979906121 sameAs 2979906121 @default.
• W2979906121 citedByCount "0" @default.
• W2979906121 crossrefType "journal-article" @default.
• W2979906121 hasAuthorship W2979906121A5007152738 @default.
• W2979906121 hasAuthorship W2979906121A5011287280 @default.
• W2979906121 hasAuthorship W2979906121A5016021915 @default.
• W2979906121 hasAuthorship W2979906121A5022153283 @default.
• W2979906121 hasAuthorship W2979906121A5044244099 @default.
• W2979906121 hasAuthorship W2979906121A5053624043 @default.
• W2979906121 hasAuthorship W2979906121A5068166657 @default.
• W2979906121 hasAuthorship W2979906121A5069161646 @default.
• W2979906121 hasAuthorship W2979906121A5072006834 @default.
• W2979906121 hasAuthorship W2979906121A5083084021 @default.
• W2979906121 hasConcept C104317684 @default.
• W2979906121 hasConcept C135763542 @default.
• W2979906121 hasConcept C153209595 @default.
• W2979906121 hasConcept C164027704 @default.
• W2979906121 hasConcept C17991360 @default.
• W2979906121 hasConcept C203014093 @default.
• W2979906121 hasConcept C2776364478 @default.
• W2979906121 hasConcept C2776396001 @default.
• W2979906121 hasConcept C2776914184 @default.
• W2979906121 hasConcept C2778690821 @default.
• W2979906121 hasConcept C502942594 @default.
• W2979906121 hasConcept C54355233 @default.
• W2979906121 hasConcept C71924100 @default.
• W2979906121 hasConcept C86803240 @default.
• W2979906121 hasConceptScore W2979906121C104317684 @default.
• W2979906121 hasConceptScore W2979906121C135763542 @default.
• W2979906121 hasConceptScore W2979906121C153209595 @default.
• W2979906121 hasConceptScore W2979906121C164027704 @default.
• W2979906121 hasConceptScore W2979906121C17991360 @default.
• W2979906121 hasConceptScore W2979906121C203014093 @default.
• W2979906121 hasConceptScore W2979906121C2776364478 @default.
• W2979906121 hasConceptScore W2979906121C2776396001 @default.
• W2979906121 hasConceptScore W2979906121C2776914184 @default.
• W2979906121 hasConceptScore W2979906121C2778690821 @default.
• W2979906121 hasConceptScore W2979906121C502942594 @default.
• W2979906121 hasConceptScore W2979906121C54355233 @default.
• W2979906121 hasConceptScore W2979906121C71924100 @default.
• W2979906121 hasConceptScore W2979906121C86803240 @default.
• W2979906121 hasLocation W29799061211 @default.
• W2979906121 hasOpenAccess W2979906121 @default.
• W2979906121 hasPrimaryLocation W29799061211 @default.
• W2979906121 hasRelatedWork W1967780335 @default.
• W2979906121 hasRelatedWork W1969802221 @default.
• W2979906121 hasRelatedWork W2005869658 @default.
• W2979906121 hasRelatedWork W2029710343 @default.
• W2979906121 hasRelatedWork W2079713295 @default.
• W2979906121 hasRelatedWork W2133618989 @default.
• W2979906121 hasRelatedWork W2270301949 @default.
• W2979906121 hasRelatedWork W2286066922 @default.
• W2979906121 hasRelatedWork W2331913905 @default.
• W2979906121 hasRelatedWork W2333383908 @default.
• W2979906121 hasRelatedWork W2466990390 @default.
• W2979906121 hasRelatedWork W2549683526 @default.
• W2979906121 hasRelatedWork W2588571617 @default.
• W2979906121 hasRelatedWork W2753089311 @default.
• W2979906121 hasRelatedWork W2788810438 @default.
• W2979906121 hasRelatedWork W2891708682 @default.
• W2979906121 hasRelatedWork W2979318585 @default.
• W2979906121 hasRelatedWork W3043147892 @default.
• W2979906121 hasRelatedWork W3135613518 @default.
• W2979906121 hasRelatedWork W44625116 @default.
• W2979906121 isParatext "false" @default.
• W2979906121 isRetracted "false" @default.
• W2979906121 magId "2979906121" @default.
• W2979906121 workType "article" @default.